Moore Capital Management LP Acquires Shares of 202,749 Zoetis Inc. $ZTS

Key Points

• Moore Capital Management acquired 202,749 Zoetis shares worth approximately $14.57 million, while institutional investors collectively own 92.8% of the company.
• Analyst sentiment is mixed, with eight Buy, nine Hold, and two Sell ratings; the consensus rating is Hold with a target price of $107.43.
• Zoetis shares opened at $77.45, near their 52-week low, after the company slightly exceeded quarterly EPS expectations but reported a 0.2% year-over-year revenue decline.

Moore Capital Management LP bought a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 202,749 shares of the company's stock, valued at approximately $14,570,000.

Several other institutional investors and hedge funds have also modified their holdings of ZTS. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $25,000. Cassaday & Co Wealth Management LLC bought a new stake in Zoetis during the 1st quarter worth about $28,000. Elyxium Wealth LLC acquired a new position in Zoetis during the 4th quarter valued at about $32,000. Root Financial Partners LLC grew its position in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company's stock worth $30,000 after buying an additional 103 shares during the period. Finally, Wellington Grp LLC boosted its stake in Zoetis by 6,675.0% in the first quarter. Wellington Grp LLC now owns 271 shares of the company's stock valued at $32,000 after acquiring an additional 267 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on ZTS shares. Zacks Research downgraded Zoetis from a "hold" rating to a "strong sell" rating in a report on Monday, August 10th. Barclays dropped their price target on Zoetis from $136.00 to $85.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 1st. TD Cowen cut their price objective on Zoetis from $104.00 to $94.00 and set a "buy" rating on the stock in a report on Tuesday, August 25th. UBS Group lowered their target price on Zoetis from $85.00 to $80.00 and set a "neutral" rating for the company in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Zoetis from $130.00 to $115.00 and set an "overweight" rating on the stock in a report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $107.43.

Zoetis Trading Up 0.1%

NYSE:ZTS opened at $77.45 on Monday. The company has a market cap of $32.00 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $156.49. The business has a 50 day moving average price of $75.57 and a two-hundred day moving average price of $95.40. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts' expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company's revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts expect that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source